ZVRAHIGH SIGNALFINANCIAL10-K

ZVRA demonstrated a dramatic improvement in operating cash flow burn while substantially expanding its asset base and cash position.

The company's operating cash flow improved dramatically from nearly $70M in outflows to minimal burn of $1.6M, suggesting either significant operational improvements or timing effects that warrant close examination. Combined with the substantial increase in cash reserves and total assets, this indicates either successful capital raising, business model improvements, or favorable working capital dynamics that have meaningfully strengthened the company's financial position.

Comparing 2026-03-09 vs 2025-03-12View on EDGAR →
FINANCIAL ANALYSIS

ZVRA's financial profile improved markedly, with operating cash burn nearly eliminated while cash reserves grew substantially to $62.4M and total assets expanded notably to $284.7M. Operating losses modestly improved despite higher SG&A expenses of $77.6M, while accounts receivable declined and inventory remained relatively stable. The overall picture signals either successful fundraising activities or significant operational improvements that have dramatically enhanced the company's liquidity position and reduced cash burn concerns.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+97.7%
-$69.7M→-$1.6M

Operating cash flow surged 97.7% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
+84.7%
$33.8M→$62.4M

Cash position surged 84.7% — strong cash generation or capital raise providing significant financial cushion.

Total Assets
Balance Sheet
+59.8%
$178.1M→$284.7M

Asset base grew 59.8% — expansion through organic growth, acquisitions, or capital deployment.

SG&A Expense
P&L
+41.5%
$54.9M→$77.6M

SG&A up 41.5% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Accounts Receivable
Balance Sheet
-36.9%
$16.1M→$10.2M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Income
P&L
+27.7%
-$87.0M→-$62.9M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Current Liabilities
Balance Sheet
+15.3%
$34.1M→$39.3M

Current liabilities rose 15.3% — increased short-term obligations, watch current ratio.

R&D Expense
P&L
+14.9%
$8.8M→$10.2M

R&D investment increased 14.9% — signals commitment to future product development, though near-term margin impact.

Inventory
Balance Sheet
-11.7%
$2.0M→$1.7M

Inventory reduced 11.7% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-12
ADDED
001-36913 ______________________________________________________________________ Zevra Therapeutics, Inc.
A s of March 6, 2026, the registr ant had 58,711,584 shares of common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 55 Item 7A.
The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and other factors described in Risk Factors and elsewhere in this report.
These risks are discussed more fully in the section titled Risk Factors .
Material risks that may affect our business, financial condition, results of operations, and trading price of our common stock include the following: Risks Related to the Commercialization of Our Approved Products and Product Candidates If we are unable to establish effective sales, marketing and distribution capabilities for our products, or if our products fail to achieve expected market acceptance, we may not be successful in commercializing such products.
The target patient population for our rare disease products is small, so we must achieve significant market share and obtain relatively high per-patient prices to be successful.
We may be subject to enforcement action if we engage in improper marketing or promotion of our products.
Product liability claims could cause us to incur substantial liabilities and adversely affect commercialization of our products.
Significant political, trade or regulatory developments, such as increased tariffs or other measures that can restrict international trade can negatively effect development and commercialization of our products and product candidates.
REMOVED
A s of March 7 , 2025, the registrant had 54,115,869 shares of common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 82 Item 7A.
The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in Risk Factors and elsewhere in this report.
These risks are discussed more fully in the section titled "Risk Factors".
Material risks that may affect our business, financial condition, results of operations, and trading price of our common stock include the following: If commercialization of our approved products, or any of our product candidates, if approved, are not successful, or we experience significant delays in commercialization, our business will be harmed.
If we are not able to obtain required regulatory approvals for any of our product candidates, or the approved labels are not sufficiently differentiated from other competing products, we will not be able to commercialize them and our ability to generate revenue or profits or to raise future capital could be limited.
Arimoclomol is currently available to Niemann-Pick disease type C patients in France, Germany, and other EU member states through our various expanded access programs ("EAPs").
EAPs are expected to remain in place until arimoclomol becomes commercially available in each of the current EAP markets.
If an EAP is terminated prior to commercialization of arimoclomol in varying jurisdictions, it will have a material adverse effect on our business, results of operations, cash flows, financial condition and/or prospects.
If we fail to maintain effective internal control over financial reporting and disclosure controls and procedures, we may not be able to accurately report our financial results or report them in a timely manner, which may adversely affect investor confidence in us and, as a result, the value of our common stock.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →